| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | GenapSys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $201.18M | Series D | 5/27/2021 | $70M | $463.55M | $7.84 | Farallon Capital Management, Soleus Capital | ||||
 | Heal | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $174.35M | Series E | 10/21/2021 | $4.5M | $134.37M | $0.03 | Undisclosed Investors | ||||
 | Kareo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $136.5M | Series H | 10/9/2018 | $10M | $414.8M | $6.86 | Undisclosed Investors | ||||
 | Memora Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.4M | Series A-1 | 4/18/2023 | $30M | $420M | $3.22 | General Catalyst, Northwell Holdings, NorthShore, Edward Elmhurst Health, PagsGroup, Andreessen Horowitz, Transformation Capital, Frist Cressey Ventures | ||||
 | Mindstrong Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $160.35M | Series C | 5/21/2020 | $100M | $703.91M | $8.01 | General Catalyst, ARCH Venture Partners, Foresite Capital, 8VC, Optum Ventures, What If Ventures | ||||
 | Nutcracker Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $244.06M | Series C | 3/14/2022 | $167.76M | $1.09B | $10.75 | ARCH Venture Partners | ||||
 | Omniome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.29M | Series C | 1/9/2020 | $60M | $511M | $4.17 | Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences | ||||
 | Paige | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.3M | Series C-1 | 3/2/2023 | $19.5M | $656.14M | $25.74 | Undisclosed Investors | ||||
 | Pathway Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $127.23M | Series E-1 | 1/5/2016 | $40M | $932.69M | $9.50 | International Business Machines | ||||
 | Proteus Digital Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.36M | Series H | 4/15/2016 | $50M | $1.64B | $15.80 | Undisclosed Investors | ||||
 | ROME Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $199M | Series B | 9/24/2021 | $149M | $321.94M | $1.49 | Johnson & Johnson Innovation, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, Raycap, Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, Alexandria Venture Investments | ||||
 | Stimwave | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $89.02M | Series E | 8/28/2020 | $3.27M | $235.28M | $16.50 | Undisclosed Investors | ||||
 | Aiolos Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.55M | Series A | 10/24/2023 | $180M | $436.12M | $1.19 | Atlas Venture, Bain Capital Life Sciences, Forbion, Sofinnova Investments, RA Capital Management | ||||
 | Applied StemCell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Cadent Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Escient Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $243.51M | Series C | 11/28/2022 | $120M | $256.49M | $0.75 | NEA, Abingworth, Forge Life Science Partners, Avego, PFM Health Sciences, The Eleven Fund, The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners, Altitude Life Science Ventures | ||||
 | FerGene | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Iora Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $400.14M | Series F | 2/10/2020 | $150M | $790.13M | $9.49 | Premji Invest, Cox Enterprises, Temasek, Devonshire Investors, .406 Ventures, Flare Capital Partners, Polaris Partners, Khosla Venture | ||||
 | Jnana Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $414.4M | Series C-2 | 11/15/2022 | $47M | $292.93M | $0.89 | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | ||||
 | Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B | 9/7/2023 | $175M | $311.65M | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | ||||
 | Nalu | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.77M | Series E | 10/9/2024 | $115.06M | $382.56M | $4.85 | Novo Holdings, Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, Aperture Venture Partners, B Capital | ||||
| Ostro | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.67M | Series B-1 | 4/23/2025 | $5.75M | $90.55M | $2.17 | Havas | ||||
 | Quartet Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.11M | Series B | 12/10/2021 | $60M | $646.74M | $11.26 | Independence, GV, Oak HC/FT | ||||
 | Tmunity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $292.52M | Series C | 6/27/2022 | $72.24M | $129.44M | $0.84 | Undisclosed Investors | ||||